These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36558775)

  • 1. Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment.
    Kowalska-Krochmal B; Mączyńska B; Rurańska-Smutnicka D; Secewicz A; Krochmal G; Bartelak M; Górzyńska A; Laufer K; Woronowicz K; Łubniewska J; Łappo J; Czwartos M; Dudek-Wicher R
    Pathogens; 2022 Nov; 11(12):. PubMed ID: 36558775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli].
    Adaleti R; Nakipoğlu Y; Arıcı N; Kansak N; Çalık Ş; Şenbayrak S; Balık R; Aksaray S
    Mikrobiyol Bul; 2023 Jul; 57(3):365-377. PubMed ID: 37462301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study.
    Karlowsky JA; Baxter MR; Walkty AJ; Lagacé-Wiens PRS; Bay D; Adam HJ; Zhanel GG
    J Antimicrob Chemother; 2022 Oct; 77(11):3035-3038. PubMed ID: 35971759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.
    Rajenderan S; Balaji V; Anandan S; Sahni RD; Tansarli GS; Falagas ME
    PLoS One; 2014; 9(7):e103253. PubMed ID: 25068396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Susceptibility of Multi-Drug Resistant
    Mączyńska B; Paleczny J; Oleksy-Wawrzyniak M; Choroszy-Król I; Bartoszewicz M
    Pathogens; 2021 Apr; 10(5):. PubMed ID: 33922754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of
    Suich J; Mawer D; van der Woude M; Wearmouth D; Burns P; Smeets T; Barlow G
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35476672
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence and Antimicrobial Susceptibility of Bacterial Uropathogens Isolated from Pediatric Patients at Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia.
    Merga Duffa Y; Terfa Kitila K; Mamuye Gebretsadik D; Bitew A
    Int J Microbiol; 2018; 2018():8492309. PubMed ID: 30386381
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Chavan R; Naphade B; Waykar B; Bhagwat S
    Microb Drug Resist; 2021 May; 27(5):678-684. PubMed ID: 33983854
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature.
    Vardakas KZ; Legakis NJ; Triarides N; Falagas ME
    Int J Antimicrob Agents; 2016 Apr; 47(4):269-85. PubMed ID: 27013000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
    Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
    J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections.
    Gopichand P; Agarwal G; Natarajan M; Mandal J; Deepanjali S; Parameswaran S; Dorairajan LN
    Infect Drug Resist; 2019; 12():2005-2013. PubMed ID: 31372008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test.
    Croughs PD; Konijnendijk-de Regt M; Yusuf E
    Microbiol Spectr; 2022 Apr; 10(2):e0250421. PubMed ID: 35352940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using Monte Carlo Simulation.
    Leelawattanachai P; Wattanavijitkul T; Paiboonvong T; Plongla R; Chatsuwan T; Usayaporn S; Nosoongnoen W; Montakantikul P
    Antibiotics (Basel); 2020 Sep; 9(9):. PubMed ID: 32961833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.
    Fajfr M; Louda M; Paterová P; Ryšková L; Pacovský J; Košina J; Žemličková H; Broďák M
    BMC Urol; 2017 Apr; 17(1):33. PubMed ID: 28446177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
    Candel FJ; Matesanz David M; Barberán J
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.